Drug Search Results
More Filters [+]

Condoliase

Alternative Names: condoliase, si-6603, si6603, si 6603
Latest Update: 2024-07-15
Latest Update Note: News Article

Product Description

Mechanisms of Action: Glycosaminoglycan Degrader

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Japan

Approved Indications: None

Known Adverse Events: None

Company: Seikagaku
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Condoliase

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Intervertebral Disc Displacement

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Discovery 6603 Study

P3

Completed

Intervertebral Disc Displacement

2022-08-03

86%

Recent News Events